Dr. Reddy's Laboratories Limited
RDYHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Dr. Reddy's Laboratories Limited focuses on Drug Manufacturers - Specialty & Generic services and products. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. Valued at $11.00B, RDY is a large-cap name in its sector. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
Market Cap
$11.00B
Beta
0.25
P/E (TTM)
30.02
P/E (Fwd)
20.07
EPS (TTM)
$0.44
EPS (Fwd)
$0.66
ROE
8.8%
ROA
4.0%
Cash
$81.43B
Total Debt
$71.95B
Free CF
-$3.91B
52W Change
-9.4%
Annual Financials
Cash vs Debt
Where RDY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RDY finished 1.32% above its 150-day moving average ($12.91) and 0.46% below its 200-day moving average ($13.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RDY overbought or oversold?
At the October 20, 2026 close, RDY's RSI(14) was 55.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $81.43B in cash and $71.95B in debt, RDY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$3.91B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 8.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $245.88B (2023) to $335.93B (2026), reflecting a 37% increase over the period.
With a beta below 0.7, Dr. Reddy's Laboratories Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RDY.